Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (-) Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 SPECTRUM Trial(Abstract 25LBA) Proffered Papers Session Head and Neck Cancer on Saturday, Sept. 24, 13:20 (1:20 p.m.) CEST, Hall K1
Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients With Metastatic Colorectal Cancer (mCRC)(Abstract 33LBA) Proffered Paper Session Personalized Medicine on Sunday, Sept. 25, 10:30 a.m. CEST, Victoria HallADDITIONAL XGEVA ABSTRACTS
Health Resource Utilization (HRU) Associated with Skeletal-related Events (SREs) by Tumor Type in Patients with Bone Metastases/lesions: European Analysis of a Prospective Multinational Observational Study(Abstract 3613) Poster Session on Saturday, Sept. 24, 9:30 a.m. - 12:00 p.m. CEST
Effect of Denosumab Treatment on Prevention of Hypercalcemia of Malignancy in Cancer Patients with Metastatic Bone Disease(Abstract 3051) Poster Session on Monday, Sept. 26, 9:30 a.m. - 12:00 p.m. CEST
Prevention of Skeletal-Related Events with Denosumab or Zoledronic Acid - Combined Analysis From 3 Registrational Trials(Abstract 3061) Poster Session on Monday, Sept. 26, 9:30 a.m. - 12:00 p.m. CESTADDITIONAL VECTIBIX ABSTRACTS
Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients with Wild-type (WT) KRAS Metastatic Colorectal Cancer (mCRC) Treated with Prior Oxaliplatin or Bevacizumab Regimens: Result
Copyright©2010 PR Newswire.
All rights reserved